Summary
Concordia International Corp (Concordia), formerly Concordia Healthcare Corp is a healthcare products provider that offers orphan drugs. The company undertakes the management and acquisition of legacy pharmaceutical products, orphan drugs and medical devices for diabetics. Its products comprise Orapred, Donnatal, Ulesfia, Zonegran, Dibenzyline, Dutoprol, Dyrenium, Fortaz, Kayexalate, Lanoxin, Parnate, Nilandron, and Uroxatral. Concordia offers products in the forms of injectables, tablets, capsules and powders. Its target treatment areas comprise endobronchial cancer, esophageal cancer, high grade dysplasia in Barrett’s esophagus, asthma and head lice infestation among others. The company operates in Oakville, Bridgetown, Lenexa, Bannockburn, and Charlottesville. Concordia is headquartered in Oakville, Ontario, Canada.
Concordia International Corp (CXR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Concordia International Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Concordia International Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Concordia International Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Concordia International Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Concordia International Corp, Medical Devices Deals, 2011 to YTD 2017 13
Concordia International Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Concordia International Corp, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Sunovion Pharma to Divest US Rights of Ciclesonide Products to Covis Pharma 17
Concordia Healthcare Acquires Four Generic Products for USD41 Million 18
Concordia Healthcare Acquires Assets from Covis Pharma for USD1.2 Billion 18
Concordia Pharmaceuticals Acquires Zonegran from Eisai for USD91.5 Million 20
Concordia Healthcare Completes Acquisition Of Donnatal From Revive Pharma For USD265.3 Million 21
Concordia Pharma Acquires Rights To Three US Pediatrics From Shionogi 22
Amdipharm Mercury Completes Acquisition Of Fucithalmic, Ophthalmic Medicine, From LEO Pharma 23
Covis Pharma To Acquire US Commercialization Rights For Five Products From sanofi-aventis 24
Pinnacle Biologics Acquires PHOTOFRIN And PHOTOBARR From Axcan Pharma 26
Venture Financing 27
Pinnacle Biologics Raises Funds Through Venture Financing 27
Covis Pharma Raises Investment From Private Investment Firms 28
Pinnacle Biologics Secures US$1.5 Million In Venture Financing 28
Private Equity 29
Concordia International May Sell its Minority Stake 29
Cinven Acquires Mercury Pharma from HgCapital for USD730 Million 30
Partnerships 31
Concordia International Enters into Co-Promotion Agreement with RedHill Biopharma 31
Pinnacle Biologics Enters into Distribution Agreement with Orphan Canada for Photofrin 32
Concordia Healthcare Enters Into Distribution Agreement With Lachlan Pharma For Ulesfia Lotion 33
Rising Pharma Enters Into Co-Marketing Agreement With Covis Pharma For Parnate 33
Pinnacle Biologics Enters Into Co-Marketing Agreement With Alkopharma 34
Licensing Agreements 35
Concordia Pharma And Shionogi Enter Into Licensing Agreement For Ulesfia 35
Covis Pharma Enters Into Licensing Agreement With GlaxoSmithKline 36
Pinnacle Oncology Enters Into Licensing Agreement With University Of Chicago For Radioprotector Technology 37
Equity Offering 38
Concordia Healthcare Raises USD520 Million in Public Offering of Shares 38
Concordia Healthcare Raises USD288 Million in Public Offering of Subscription Receipts 39
Concordia Healthcare Completes Public Offering Of Shares For US$61 Million 40
Concordia Healthcare Announces Private Placement Of Securities For US$29 Million 41
Debt Offering 42
Concordia Raises USD266 Million in Public Offering of 9% Notes Due 2022 42
Concordia Healthcare Raises USD790 Million in Private Placement of 9.5% Notes Due 2022 43
Concordia Healthcare Raises USD735 Million in Private Placement of 7% Notes Due 2023 43
Asset Transactions 44
IGI Labs Acquires Three Injectable Products from Concordia Pharma for USD11 Million 44
Concordia Healthcare Acquires Assets from Covis Pharma for USD1.2 Billion 45
Kadmon Acquires Rights To Salirasib From Concordia Pharma 47
Acquisition 48
Concordia Healthcare Acquires Amdipharm Mercury for USD3.54 Billion 48
Amdipharm Mercury Acquires Boucher and Muir 50
Amdipharm Mercury acquires Primegen 51
Mercury Pharma Acquires Focus Pharma 51
Concordia Healthcare Acquires Pinnacle Biologics 52
Amdipharm Mercury Acquires Abcur, Specialty Pharma Company 54
Mercari Acquisition To Acquire Concordia Healthcare In Reverse Takeover Transaction 55
Concordia International Corp - Key Competitors 57
Key Employees 58
Locations And Subsidiaries 59
Head Office 59
Other Locations & Subsidiaries 59
Recent Developments 60
Financial Announcements 60
May 10, 2017: Concordia International Announces First Quarter 2017 Results 60
Mar 15, 2017: Concordia International Announces Fourth Quarter and Fiscal 2016 Results 63
Nov 07, 2016: Concordia International Announces Third Quarter 2016 Results 65
Aug 12, 2016: Concordia International Announces Second Quarter 2016 Results 68
May 13, 2016: Concordia Healthcare Announces First Quarter 2016 Results and Acquisition of Four Products with Global Rights 71
Mar 23, 2016: Concordia Healthcare Announces Fourth Quarter And Fiscal 2015 Results 74
Corporate Communications 77
May 04, 2017: Concordia International Announces Two New Appointments to the Board of Directors 77
Apr 26, 2017: Concordia International Appoints David Price as Chief Financial Officer 78
Jan 04, 2017: RedHill and Concordia sign co-promotion agreement for Donnatal drug promotion 79
Nov 02, 2016: Concordia International announces new leadership appointments 80
Oct 21, 2016: Concordia International Announces CEO Transition Plan 81
Oct 13, 2016: Concordia International Appoints Allan Oberman to Board of Directors 82
Mar 23, 2016: Concordia Healthcare Announces Board Appointment 83
Legal and Regulatory 84
Mar 06, 2017: Concordia International Grant of Treble Damages Further Vindicates Marketing Rights of its Donnatal Brand 84
Oct 25, 2016: Concordia International Announces Communication With CMA 85
Government and Public Interest 86
May 31, 2017: Concordia International Announces Results of First CMA Stop/Go Decision 86
Product News 87
Jun 17, 2016: Concordia Healthcare Announces PDT With Photofrin Data And Provides Corporate Update 87
Product Approvals 88
Jun 30, 2016: Concordia International Announces FDA Approval for New Photofrin Laser 88
Other Significant Developments 89
Jun 21, 2017: Concordia International Provides Update on Development of Long-Term Growth Strategy 89
Dec 19, 2016: Concordia International Provides Business Update 90
Aug 03, 2016: Concordia International Confirms That Strategic Review is Ongoing and Provides Update on its Business 92
Jul 13, 2016: Concordia International Provides Additional Disclosure in Relation to Brexit’s Impact on its Business 93
Jun 28, 2016: Concordia Healthcare Announces Name Change To Concordia International And Comments On Brexit’s Impact On The Company’s Business 94
Jan 11, 2016: Concordia Healthcare Provides Corporate Update 95
Appendix 96
Methodology 96
About GlobalData 96
Contact Us 96
Disclaimer 96
List of Tables
Concordia International Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Concordia International Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Concordia International Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Concordia International Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Concordia International Corp, Deals By Therapy Area, 2011 to YTD 2017 11
Concordia International Corp, Medical Devices Deals, 2011 to YTD 2017 13
Concordia International Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Sunovion Pharma to Divest US Rights of Ciclesonide Products to Covis Pharma 17
Concordia Healthcare Acquires Four Generic Products for USD41 Million 18
Concordia Healthcare Acquires Assets from Covis Pharma for USD1.2 Billion 18
Concordia Pharmaceuticals Acquires Zonegran from Eisai for USD91.5 Million 20
Concordia Healthcare Completes Acquisition Of Donnatal From Revive Pharma For USD265.3 Million 21
Concordia Pharma Acquires Rights To Three US Pediatrics From Shionogi 22
Amdipharm Mercury Completes Acquisition Of Fucithalmic, Ophthalmic Medicine, From LEO Pharma 23
Covis Pharma To Acquire US Commercialization Rights For Five Products From sanofi-aventis 24
Pinnacle Biologics Acquires PHOTOFRIN And PHOTOBARR From Axcan Pharma 26
Pinnacle Biologics Raises Funds Through Venture Financing 27
Covis Pharma Raises Investment From Private Investment Firms 28
Pinnacle Biologics Secures US$1.5 Million In Venture Financing 28
Concordia International May Sell its Minority Stake 29
Cinven Acquires Mercury Pharma from HgCapital for USD730 Million 30
Concordia International Enters into Co-Promotion Agreement with RedHill Biopharma 31
Pinnacle Biologics Enters into Distribution Agreement with Orphan Canada for Photofrin 32
Concordia Healthcare Enters Into Distribution Agreement With Lachlan Pharma For Ulesfia Lotion 33
Rising Pharma Enters Into Co-Marketing Agreement With Covis Pharma For Parnate 33
Pinnacle Biologics Enters Into Co-Marketing Agreement With Alkopharma 34
Concordia Pharma And Shionogi Enter Into Licensing Agreement For Ulesfia 35
Covis Pharma Enters Into Licensing Agreement With GlaxoSmithKline 36
Pinnacle Oncology Enters Into Licensing Agreement With University Of Chicago For Radioprotector Technology 37
Concordia Healthcare Raises USD520 Million in Public Offering of Shares 38
Concordia Healthcare Raises USD288 Million in Public Offering of Subscription Receipts 39
Concordia Healthcare Completes Public Offering Of Shares For US$61 Million 40
Concordia Healthcare Announces Private Placement Of Securities For US$29 Million 41
Concordia Raises USD266 Million in Public Offering of 9% Notes Due 2022 42
Concordia Healthcare Raises USD790 Million in Private Placement of 9.5% Notes Due 2022 43
Concordia Healthcare Raises USD735 Million in Private Placement of 7% Notes Due 2023 43
IGI Labs Acquires Three Injectable Products from Concordia Pharma for USD11 Million 44
Concordia Healthcare Acquires Assets from Covis Pharma for USD1.2 Billion 45
Kadmon Acquires Rights To Salirasib From Concordia Pharma 47
Concordia Healthcare Acquires Amdipharm Mercury for USD3.54 Billion 48
Amdipharm Mercury Acquires Boucher and Muir 50
Amdipharm Mercury acquires Primegen 51
Mercury Pharma Acquires Focus Pharma 51
Concordia Healthcare Acquires Pinnacle Biologics 52
Amdipharm Mercury Acquires Abcur, Specialty Pharma Company 54
Mercari Acquisition To Acquire Concordia Healthcare In Reverse Takeover Transaction 55
Concordia International Corp, Key Competitors 57
Concordia International Corp, Key Employees 58
Concordia International Corp, Subsidiaries 59List of Figures
Concordia International Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Concordia International Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Concordia International Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Concordia International Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Concordia International Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Concordia International Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 9
Concordia International Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Concordia International Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Concordia International Corp, Medical Devices Deals, 2011 to YTD 2017 13
